Javier de Castro

27.3k total citations · 2 hit papers
304 papers, 8.3k citations indexed

About

Javier de Castro is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Javier de Castro has authored 304 papers receiving a total of 8.3k indexed citations (citations by other indexed papers that have themselves been cited), including 174 papers in Oncology, 163 papers in Pulmonary and Respiratory Medicine and 66 papers in Molecular Biology. Recurrent topics in Javier de Castro's work include Lung Cancer Treatments and Mutations (132 papers), Lung Cancer Research Studies (67 papers) and Lung Cancer Diagnosis and Treatment (56 papers). Javier de Castro is often cited by papers focused on Lung Cancer Treatments and Mutations (132 papers), Lung Cancer Research Studies (67 papers) and Lung Cancer Diagnosis and Treatment (56 papers). Javier de Castro collaborates with scholars based in Spain, United States and France. Javier de Castro's co-authors include Cristóbal Belda-Iniesta, Manuel González-Barón, Paloma Cejas, Juan Ángel Fresno Vara, E. Casado, Jaime Feliú, Rosario Perona, Dolores Isla, Enrique Casado and Inmaculada Ibañez de Cáceres and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Javier de Castro

283 papers receiving 8.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

PI3K/Akt signalling pathway and cancer

2003 1.9k citations E. Casado, Javier de Castro et al. profile →
Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133)

2021 484 citations Stephen V. Liu, Martin Reck et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by Javier de Castro

Since Specialization

Citations

This map shows the geographic impact of Javier de Castro's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Javier de Castro with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Javier de Castro more than expected).

Fields of papers citing papers by Javier de Castro

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Javier de Castro. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Javier de Castro. The network helps show where Javier de Castro may publish in the future.

Co-authorship network of co-authors of Javier de Castro

This figure shows the co-authorship network connecting the top 25 collaborators of Javier de Castro. A scholar is included among the top collaborators of Javier de Castro based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Javier de Castro. Javier de Castro is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	210P: Prognostic Value of minimal residual disease in the NADIM II trial 2025 ·Journal of Thoracic Oncology ·Roberto Serna‐Blasco, (unknown), J.L. González-Larriba, (unknown), Reyes Bernabé, (unknown), Virginia Calvo, (unknown), (unknown), Javier de Castro, Carlos Aguado, Ramón Palmero, Florentino Hernándo, (unknown), M. Lázaro, (unknown), (unknown), (unknown), (unknown), (unknown)	1
2	Peripheral memory B cell population maintenance and long-term survival after perioperative chemoimmunotherapy in NSCLC (NADIM trial) 2025 ·OncoImmunology ·(unknown), (unknown), Ernest Nadal, (unknown), (unknown), (unknown), Bartomeu Massutí, Aránzazu García‐Grande, (unknown), Amelia Insa, Javier de Castro, (unknown), Margarita Majem, Alex Martínez‐Martí, Diego Megı́as, (unknown), Ana Collazo-Lorduy, Virginia Calvo, Mariano Provencio, Alberto Cruz‐Bermúdez	0
3	Lenvatinib plus pembrolizumab in pretreated metastatic B3 thymoma and thymic carcinoma (PECATI): a single-arm, phase 2 trial 2025 ·The Lancet Oncology ·Jordi Remón, Paolo Bironzo, Nicolas Girard, L. Bigay-Gamé, Óscar Juan, Javier de Castro, Noemı́ Reguart, Laurent Greillier, Sophie Cousin, Éric Dansin, Margarita Majem, Reyes Bernabé, Joaquín Mosquera, (unknown), (unknown), Daniel Alcalá-López, (unknown), Luisella Righi, Silvia Novello, Benjamin Besse	1
4	ctDNA Dynamics and Mechanisms of Acquired Resistance in Patients Treated with Osimertinib with or without Bevacizumab from the Randomized Phase II ETOP-BOOSTER Trial 2024 ·Clinical Cancer Research ·Ross A. Soo, Urania Dafni, Ji‐Youn Han, Byoung Chul Cho, Ernest Nadal, (unknown), Enric Carcereny, Javier de Castro, (unknown), Linda Coate, Mariano Provencio, Christian Britschgi, (unknown), (unknown), Roswitha Kammler, Stephen P. Finn, Solange Peters, Rolf A. Stahel, (unknown)	1
5	Cardiovascular toxicity of checkpoint inhibitors: review of associated toxicity and design of the Spanish Immunotherapy Registry of Cardiovascular Toxicity 2023 ·Clinical & Translational Oncology ·Eduardo Zatarain‐Nicolás, Pilar Martı́n, Iván Márquez‐Rodas, Juan Antonio Virizuela, Ana Martín‐Garcia, Cristina Mitroi, Juan Cosı́n-Sales, Vivencio Barrios, Fátima Sánchez‐Cabo, Borja Ibáñez, Javier de Castro, Teresa López‐Fernández	4
6	New update to the guidelines on testing predictive biomarkers in non-small-cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology 2022 ·Clinical & Translational Oncology ·Dolores Isla, María D. Lozano, Luis Paz‐Ares, Clara Salas, Javier de Castro, Esther Conde, Enriqueta Felip, Javier Gómez‐Román, Pilar Garrido, Ana B. Enguita	23
7	Final efficacy and safety data, and exploratory molecular profiling from the phase III ALUR study of alectinib versus chemotherapy in crizotinib-pretreated ALK-positive non-small-cell lung cancer 2022 ·ESMO Open ·Jennifer Moriatis Wolf, Åslaug Helland, In‐Jae Oh, M.R. Migliorino, Rafał Dziadziuszko, Anna Wrona, Javier de Castro, Julien Mazières, Frank Griesinger, (unknown), Andrés F. Cardona, Thorsten Ruf, Kerstin Trunzer, Vlatka Smoljanović, Silvia Novello	25
8	Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133) breakdown → 2021 ·Journal of Clinical Oncology ·Stephen V. Liu, Martin Reck, Aaron S. Mansfield, Tony Mok, Arnaud Scherpereel, Niels Reinmuth, Marina Chiara Garassino, Javier de Castro, Raffaele Califano, Makoto Nishio, Francesco Orlandi, Jorge Alatorre-Alexander, Ticiana Leal, Ying Cheng, Jong Seok Lee, Sivuonthanh Lam, Mark L. McCleland, Yu Deng, See Phan, Leora Horn	484
9	PECATI: A Multicentric, Open-Label, Single-Arm Phase II Study to Evaluate the Efficacy and Safety of Pembrolizumab and Lenvatinib in Pretreated B3-Thymoma and Thymic Carcinoma Patients 2021 ·Clinical Lung Cancer ·Jordi Remón, Nicolas Girard, Silvia Novello, Javier de Castro, L. Bigay-Gamé, Reyes Bernabé, Laurent Greillier, Joaquín Mosquera, Sophie Cousin, Óscar Juan, (unknown), Benjamin Besse	24
10	Targeted Therapy Moves to Earlier Stages of Non-Small-Cell Lung Cancer: Emerging Evidence, Controversies and Future Challenges 2021 ·Future Oncology ·Xabier Mielgo-Rubio, M. Martín, Jordi Remón, Oliver Higuera, Virginia Calvo, J.R. Jarabo, Esther Conde, J. Luna, Mariano Provencio, Javier de Castro, Fernando López‐Ríos, Florentino Hernándo, Felipe Couñago	16
11	Sequential blinded treatment decisions in ALK-positive non-small cell lung cancers in the era of precision medicine 2020 ·Clinical & Translational Oncology ·Jordi Remón, Fabrizio Tabbò, Beatriz Jiménez, Ana Collazo, Javier de Castro, Silvia Novello	5
12	Immunotherapy Moves to the Early-Stage Setting in Non-Small Cell Lung Cancer: Emerging Evidence and the Role of Biomarkers 2020 ·Cancers ·Xabier Mielgo-Rubio, Virginia Calvo, J. Luna, Jordi Remón, M. Martín, Pedro Berraondo, J.R. Jarabo, Oliver Higuera, Esther Conde, Javier de Castro, Mariano Provencio, Florentino Hernándo, Fernando López‐Ríos, Felipe Couñago	9
13	Treatment strategy optimization for patients with non-small-cell lung cancer harboring EGFR mutation: a Delphi consensus 2020 ·Clinical & Translational Oncology ·Dolores Isla, Javier de Castro, Rosario García‐Campelo, Margarita Majem, David Vicente, Óscar Juan	1
14	Biodiversidad marina en isla Lobos de Tierra, Lambayeque (agosto, 2017). 2020 ·Instituto del Mar del Perú - IMARPE ·(unknown), (unknown), Javier de Castro	1
15	Treatment options beyond immunotherapy in patients with wild-type lung adenocarcinoma: a Delphi consensus 2019 ·Clinical & Translational Oncology ·Dolores Isla, Javier de Castro, Rosario García‐Campelo, P. Lianes, Enriqueta Felip, Pilar Garrido, Luis Paz‐Ares, José Trigo	11
16	Efficacy of tyrosine kinase inhibitors in EGFR-mutant lung cancer women in a real-world setting: the WORLD07 database 2017 ·Clinical & Translational Oncology ·Jordi Remón, Dolores Isla, Pilar Garrido, Javier de Castro, Margarita Majem, Núria Viñolas, Á. Artal, Enric Carcereny, M.R. García-Campelo, P. Lianes, Mariano Provencio, Óscar Juan, Pilar Díz, Ricardo Blanco, Rafael López Castro, I. Maestu, Catalina Vadell, Enriqueta Felip	4
17	Phase I/II trial of vorinostat (SAHA) and erlotinib for non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations after erlotinib progression 2014 ·Lung Cancer ·Noemı́ Reguart, Rafael Rosell, Felipe Cardenal, Andrés F. Cardona, Dolores Isla, Ramón Palmero, Teresa Morán, Christian Rolfo, (unknown), Amelia Insa, Enric Carcereny, Margarita Majem, Javier de Castro, Cristina Queralt, Miguel Ángel Molina‐Vila, Miquel Tarón	72
18	A Combined Strategy of SAGE and Quantitative PCR Provides a 13-Gene Signature that Predicts Preoperative Chemoradiotherapy Response and Outcome in Rectal Cancer 2011 ·Clinical Cancer Research ·E. Casado, Víctor Moreno, José Javier Sánchez, Montserrat Blanco, Joan Maurel, Jaime Feliú, Carlos Fernández-Martos, Javier de Castro, Beatriz Castelo, Cristóbal Belda-Iniesta, María Sereno, (unknown), Emilio Burgos, Miguel Ángel García‐Cabezas, Noemí Manceñido, Rosa Miquel, Damián García‐Olmo, Manuel González-Barón, Paloma Cejas	25
19	[Levels of blood pepsinogen I in the offspring of patients with duodenal ulcer]. 1991 ·PubMed ·(unknown), (unknown), Javier de Castro, (unknown), C Callegari	1
20	The use of almitrine following potentialized analgesic. Anesthesia based upon alfentanil and flunitrazepam or etomidate. 1979 ·Munich Personal RePEc Archive (Ludwig Maximilian University of Munich) ·Javier de Castro, (unknown), (unknown)	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact